Establish Early Development Strategies For Therapeutics Proteins - ERP Spain.com - España y América Latina

Presented by Sorina Morar-Mitrica, Principal Fellow Sr Drug Product Lead Early Phase Biologics at Novartis Thorsten Lorenz studied Biochemistry at the University of Bochum in Germany. He performed his PhD work at the Max Planck Institute for Medical Research in Heidelberg and afterwards joined Novartis as postdoctoral fellow. In 2011, he took the lead for the buildup of a laboratory for protein characterization and pre-formulation assessment. After taking roles of increasing responsibility in the unit, Thorsten was appointed Team Head Developability Assessment in 2017, responsible for the assessment of molecular properties, downstream process and stability characteristics as well as immunogenicity and in vivo stability risks for the Novartis Biologics pipeline at the transition from Research to Development. Since April 2019, Thorsten has been leading the Early Drug Substance Development group in Novartis Technical Development New Biologics Entities. Follolwed by an Industry perspective presented by Renee Tobias, Director of Marketing, Halo Labs